NewAmsterdam Pharma Company N.V. (NAMS)
Company Info
Highlights
$1.98B
-$1.84
$47.14M
$47.14M
-$255.79M
$14.06 - $27.29
$42.63
7.12%
10.45
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
NewAmsterdam Pharma Company N.V. (NAMS) returned -29.53% year-to-date (YTD) and -2.21% over the past 12 months.
NAMS
-29.53%
-5.33%
-8.77%
-2.21%
N/A
N/A
N/A
^GSPC (Benchmark)
0.51%
6.15%
-2.00%
12.92%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of NAMS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -13.27% | -5.79% | -2.52% | -6.55% | -5.33% | -29.53% | |||||||
| 2024 | 83.26% | 11.58% | 3.55% | -7.78% | -14.03% | 2.45% | -10.88% | -4.09% | 1.10% | 2.53% | 16.63% | 29.47% | 130.08% |
| 2023 | 22.71% | -1.31% | 0.45% | 7.32% | -2.60% | -14.21% | -3.11% | -10.50% | -10.28% | -2.70% | 8.44% | 14.45% | 2.48% |
| 2022 | -21.74% | 34.57% | 5.31% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of NAMS is 45, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for NewAmsterdam Pharma Company N.V. (NAMS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the NewAmsterdam Pharma Company N.V.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the NewAmsterdam Pharma Company N.V. was 66.23%, occurring on Oct 25, 2023. Recovery took 58 trading sessions.
The current NewAmsterdam Pharma Company N.V. drawdown is 31.94%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -66.23% | Jan 31, 2023 | 186 | Oct 25, 2023 | 58 | Jan 19, 2024 | 244 |
| -44.01% | Dec 18, 2024 | 77 | Apr 10, 2025 | — | — | — |
| -37.1% | Feb 28, 2024 | 146 | Sep 25, 2024 | 33 | Nov 11, 2024 | 179 |
| -27.63% | Nov 15, 2024 | 14 | Dec 5, 2024 | 3 | Dec 10, 2024 | 17 |
| -21.74% | Nov 25, 2022 | 4 | Nov 30, 2022 | 11 | Dec 15, 2022 | 15 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of NewAmsterdam Pharma Company N.V. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of NewAmsterdam Pharma Company N.V., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 30.9% positive surprise.
Valuation
The Valuation section provides an overview of how NewAmsterdam Pharma Company N.V. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for NAMS relative to other companies in the Biotechnology industry. Currently, NAMS has a P/S ratio of 42.0. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for NAMS in comparison with other companies in the Biotechnology industry. Currently, NAMS has a P/B value of 2.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |